Granules India Ltd share price logo

Granules India Ltd (GRANULES)


Get free price alerts. Set up your Free investment account to get Live Prices.
Q3 '23 Results

Analyst Rating

based on 7 analysts








Based on 7 analysts offering long term price targets for Granules India Ltd. An average target of ₹488.14

Source: S&P Global Market Intelligence

Granules India Ltd Share analysis

Source: S&P Global Market Intelligence


  • Day's Low

  • 52 Week's Low

    52 Week's High

1 Month Return+ 9.02 %
3 Month Return+ 22.01 %
1 Year Return+ 66.62 %
Previous Close₹514.70
Upper Circuit-
Lower Circuit-
Market Cap₹12,474.72Cr

Key Statistics

P/E Ratio30.77
PEG Ratio-7.14
Market Cap₹12,474.72 Cr
P/B Ratio2.61

Mutual Fund Holdings

Funds HoldingsPrev. 6M
Quant Active Fund Growth Option Direct PlanQuant Active Fund Growth Option Direct Plan1.48%
Aditya Birla Sun Life Pure Value Fund Direct Plan GrowthAditya Birla Sun Life Pure Value Fund Direct Plan Growth2.02%
Quant Small Cap Fund Growth Option Direct PlanQuant Small Cap Fund Growth Option Direct Plan0.32%
Axis India Manufacturing Fund Direct GrowthAxis India Manufacturing Fund Direct Growth1.09%
Axis Small Cap Fund Direct GrowthAxis Small Cap Fund Direct Growth0.28%

Company Information

Granules India Limited is a large-scale vertically-integrated company found in March 1991. It manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. The company has a strong presence in off-patent drugs, first-line defence products such as Paracetamol, Ibuprofen, Metformin, and Guaifenesin, as well as a global presence in over 80 countries and 250 customers. It also has a 15,000 sq. ft. research center in Pragathi Nagar, Hyderabad and has completed expansion projects in Gagillapur and Visakhapatnam. In FY 2014-15, the company crossed Rs 1200 crore in revenue, made its first acquisition, and increased its PFI capacity by 4000 tons / annum. During 2015-16 it initiated construction of 7000 TPA Metformin and 2000 TPA Guaifenesin API block, and has a total of 22 EDMF/CEP and 44 ANDA filings with US FDA. In FY 2017 the company received Establishment Inspection Report from US FDA for its Jeedimetla plant and license from the Drug Enforcement Agency for its Virginia facility. In FY 2018, it crossed Rs 1400 crore in revenue and initiated commercial production of Metaformin and Paracetamol API at its Bonthapally facility. The company also successfully received 7 ANDAs approvals from US FDA. In FY 2019, Granules India initiated buyback programme, with the Board of Directors approving a buyback of up to 12.5 million equity shares on 21 January 2020. The Company has divested its entire 50% shareholding in GranulesBiocause Pharmaceutical Co. Ltd and Granules Omnichem Private Ltd. for a consideration of Rs 111.2 crore. During the year 2021, Granules Pharmaceuticals Inc. announced a voluntary recall of 12 batches of Metformin Hydrochloride Extended Release tablets USP 750 mg, out of caution. In 2022, the Company completed the largest single manufacturing site for Multiple Unit Pellet System MUPS at its Gagillapur facility and capacity expansion for manufacturing multiple APIs at Unit V Visakhapatnam. In a span of over 30 years, Granules India has firmly established its leadership in the off-patent drugs segment, and a strong presence in first line of defense products, creating a global presence in over 80 countries, servicing over 250 customers and filing 66 EDMF/CE

Share Price: ₹515.40 per share as on 12 Jul, 2024 10:57 AM
Market Capitalisation: ₹12,474.72Cr as of today
Revenue: ₹1,175.78Cr as on March 2024 (Q1 24)
Net Profit: ₹129.65Cr as on March 2024 (Q1 24)
Listing date: 20 Jun, 2005
Chairperson Name: C Krishna Prasad
OrganisationGranules India Ltd
E-voting on sharesClick here to vote

Key events for Granules India Ltd

  • Granules India Stock Shows Strong Breakout - 05 Jul, 2024

    Granules India Ltd's stock has given a strong breakout above its recent resistance mark and is set for an upside move towards 530. The stock has added around 12.86% in the last one month and is up for a third straight session. Nifty Pharma index, of which Granules India Ltd is a constituent, has also shown growth.

  • Yes Securities Bullish on Granules India Ltd - 28 Jun, 2024

    Yes Securities recommends buying Granules India Ltd as the stock is attempting to surpass the peak of the current month and has witnessed a follow-through move post bullish anchor column and ABC breakout.

  • Granules India Focuses on Value-Added Products, Sharekhan Reiterates Buy Rating - 27 Jun, 2024

    Granules India is focusing on value-added products to increase EBITDA margins and diversifying from being an API company to a formulations company. Sharekhan has reiterated a Buy rating with a target price of Rs. 600. The stock achieved a robust breakout above its all-time high and shows strong momentum.

  • Granules India Poised for Upside Move, Says Analyst - 22 Jun, 2024

    According to technical analyst Riyank Arora at Mehta Equities, Granules India is set for an upside move after breaking out above its all-time high resistance mark of Rs 485.95. With the stock making higher highs and higher lows and volume spiking up, it could reach potential targets of Rs 525.00 and above.

  • Granules India to Pay Dividend of Rs 1.50 per Share - 19 Jun, 2024

    Granules India will pay a dividend of Rs 1.50 per share on September 5th, with a yield of 0.3%. The company's earnings easily cover the dividend and are forecasted to rise by 96.7% over the next year. Granules India has a sustained record of paying dividends, growing its distributions at a yearly rate of about 22% over the last decade. With low payout ratios and decent growth, this looks like it could be a good dividend opportunity.

  • Sharekhan Recommends BUY on Granules India with Target Price of Rs. 515 - 12 Jun, 2024

    Granules India's Q4 earnings were mixed, but the company has guided to launch a record number of new products in North America and has meaningful products in its portfolio. Sharekhan recommends a BUY with a target price of Rs. 515 per share.

  • Granules India Ltd Up for Third Straight Session - 07 Jun, 2024

    Granules India Ltd is up 1.77% on the NSE, adding around 16% in the last month. The benchmark NIFTY and Sensex are also up around 1.78% and 1.87%, respectively. PE of the stock is 26.01 based on TTM earnings ending March 24.

Insights on Granules India Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    Price Rise


    In the last 3 months, GRANULES stock has moved up by 22.9%


    FII Holding Up


    Foreign Institutions have increased holdings from 18.78% to 19.57% in Mar 2024 quarter


    Profit Spike


    Netprofit is up for the last 4 quarters, 47.9 Cr → 129.65 Cr (in ₹), with an average increase of 25.0% per quarter


    Revenue Rich


    Revenue is up for the last 2 quarters, 1.15K Cr → 1.17K Cr (in ₹), with an average increase of 1.8% per quarter


    MF Holding Up


    Mutual Funds have increased holdings from 7.05% to 7.09% in Mar 2024 quarter

  • imgNO EFFECT

    Against Peers


    In the last 1 year, Zydus Lifesciences Ltd has given 101.8% return, outperforming this stock by 34.6%

  • imgNO EFFECT

    Against Peers


    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 139.1% return, outperforming this stock by 100.2%

  • imgNO EFFECT

    Promoter Holding Unchanged


    Promoters holdings remained unchanged at 41.96% of holdings in Mar 2024 quarter


    Retail Holding Down


    Retail Investor have decreased holdings from 29.10% to 27.76% in Mar 2024 quarter

Company Financials

Value in ₹ crore
Q'1 24Q/Q Change
Net Income
Net Profit Margin
2023Y/Y Change
Net Income
Net Profit Margin
Value in ₹ crore
2023Y/Y Change
Total Assets
Total Liabilities
Value in ₹ crore
2023Y/Y Change
Operating Cash Flow

Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Key Indicators

Granules India Ltd Valuation

Granules India Ltd in the last 5 years

  • Overview

  • Trends

Lowest (8.05x)

July 25, 2019

Today (30.77x)

July 11, 2024

Industry (63.74x)

July 11, 2024

Highest (31.44x)

July 5, 2024


Earnings and Dividends

  • Granules India Ltd Earnings Results

    Granules India Ltd’s net profit jumped 8.39% since last year same period to ₹129.65Cr in the Q4 2023-2024. On a quarterly growth basis, Granules India Ltd has generated 3.18% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Granules India Ltd Dividends May,2024

    In the quarter ending March 2024, Granules India Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.58%.

    Read More about Dividends

Technicals Summary





Granules India Ltd is currently in a Bullish trading position according to technical analysis indicators.

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Granules India Ltd shares.

Granules India Ltd (GRANULES) share price today is ₹515.4

Granules India Ltd is listed on NSE

Granules India Ltd is listed on BSE

  • Today’s highest price of Granules India Ltd is ₹515.4.
  • Today’s lowest price of Granules India Ltd is ₹515.2.

PE Ratio of Granules India Ltd is 30.77

PE ratio = Granules India Ltd Market price per share / Granules India Ltd Earnings per share

Today’s traded volume of Granules India Ltd(GRANULES) is 3.97L.

Today’s market capitalisation of Granules India Ltd(GRANULES) is ₹12474.72Cr.

Granules India Ltd(GRANULESPrice
52 Week High
52 Week Low

Granules India Ltd(GRANULES) share price is ₹515.4. It is down -2.87% from its 52 Week High price of ₹530.65

Granules India Ltd(GRANULES) share price is ₹515.4. It is up 79.14% from its 52 Week Low price of ₹287.7

Granules India Ltd(GRANULESReturns
1 Day Returns
1 Month Returns
3 Month Returns
1 Year Returns